Physician profile
Ernest K Maina
NPI 1740751445
$1,876.27
in general payments reported to CMS, 2019-2025
11 companies · $587 in 2025
The $587 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $494 · 2024: $796 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,095.76 | 2023-2025 | |
| Novo Nordisk INC | $256.39 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $195.63 | 2024 | Airsupra |
| Pharmacosmos Therapeutics INC. | $104.17 | 2023 | Monoferric |
| Boston Scientific Corporation | $83.28 | 2024-2025 | Bodyguardian |
| Antares Pharma, INC. | $44.49 | 2025 | Xyosted |
| Lundbeck LLC | $27.43 | 2025 | Rexulti |
| Lilly USA, LLC | $22.26 | 2023 | Mounjaro |
| Supernus Pharmaceuticals, INC. | $18.11 | 2025 | Qelbree |
| Novartis Pharmaceuticals Corporation | $14.64 | 2023 | |
| Exact Sciences Corporation | $14.11 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Maina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.